European Association for the Study of the Liver. EASL clinical practice guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017;67(1):145–72. https://www.ncbi.nlm.nih.gov/pubmed/28427765
Levy C, Bowlus CL, Carey EJ, DeMuth G, Deane K, Mayo MJ, et al. Mo1451 - Primary Biliary Cholangitis (PBC) in the U.S.: Real World Effectiveness of Obeticholic Acid in Target-PBC. Gastroenterology 2018;154(6):S-1210. https://doi.org/10.1016/S0016-5085(18)33999-4
Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2019;69(1):394–419. https://www.ncbi.nlm.nih.gov/pubmed/30070375
Peters Y, Hooshmand-Rad R, Pencek R, Owens-Grillo J, Marmon T, MacConell L, et al. Long-term safety of OCA in patients with PBC [abstract 644]. In: The 66th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting, 13-17 November 2015, San Francisco, California. Hepatology 2015;62(1 (Suppl.)):530A.
Vierling JM, Hirschfield GM, Jones D, Groszmann RJ, Kowdley KV, Pencek R, et al. Efficacy obeticholic acid treatment in patients with primary biliary cholangitis with cirrhosis [abstract 366]. In: American Association for the Study of Liver Diseases: The Liver Meeting, 11-15 November 2016, Boston, Massachusetts. Hepatology 2016;64(1 (Suppl.)):187A.
